778 related articles for article (PubMed ID: 27506934)
21. Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34
Wang YY; Chen WL; Weng XQ; Sheng Y; Wu J; Hao J; Liu ZY; Zhu YM; Chen B; Xiong SM; Chen Y; Chen QS; Sun HP; Li JM; Wang J
Stem Cells Dev; 2017 Oct; 26(20):1460-1467. PubMed ID: 28810819
[TBL] [Abstract][Full Text] [Related]
22. Ginsenoside Rg1 Inhibits Cell Proliferation and Induces Markers of Cell Senescence in CD34+CD38- Leukemia Stem Cells Derived from KG1α Acute Myeloid Leukemia Cells by Activating the Sirtuin 1 (SIRT1)/Tuberous Sclerosis Complex 2 (TSC2) Signaling Pathway.
Tang YL; Zhang CG; Liu H; Zhou Y; Wang YP; Li Y; Han YJ; Wang CL
Med Sci Monit; 2020 Feb; 26():e918207. PubMed ID: 32037392
[TBL] [Abstract][Full Text] [Related]
23. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
24. MiR-29b/Sp1/FUT4 axis modulates the malignancy of leukemia stem cells by regulating fucosylation via Wnt/β-catenin pathway in acute myeloid leukemia.
Liu B; Ma H; Liu Q; Xiao Y; Pan S; Zhou H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):200. PubMed ID: 31097000
[TBL] [Abstract][Full Text] [Related]
25. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
Kikushige Y; Shima T; Takayanagi S; Urata S; Miyamoto T; Iwasaki H; Takenaka K; Teshima T; Tanaka T; Inagaki Y; Akashi K
Cell Stem Cell; 2010 Dec; 7(6):708-17. PubMed ID: 21112565
[TBL] [Abstract][Full Text] [Related]
26. miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1.
Zhang Y; Zhou SY; Yan HZ; Xu DD; Chen HX; Wang XY; Wang X; Liu YT; Zhang L; Wang S; Zhou PJ; Fu WY; Ruan BB; Ma DL; Wang Y; Liu QY; Ren Z; Liu Z; Zhang R; Wang YF
Sci Rep; 2016 Feb; 6():19995. PubMed ID: 26847520
[TBL] [Abstract][Full Text] [Related]
27. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia.
Bakker AB; van den Oudenrijn S; Bakker AQ; Feller N; van Meijer M; Bia JA; Jongeneelen MA; Visser TJ; Bijl N; Geuijen CA; Marissen WE; Radosevic K; Throsby M; Schuurhuis GJ; Ossenkoppele GJ; de Kruif J; Goudsmit J; Kruisbeek AM
Cancer Res; 2004 Nov; 64(22):8443-50. PubMed ID: 15548716
[TBL] [Abstract][Full Text] [Related]
28. Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy.
Nishida Y; Maeda A; Chachad D; Ishizawa J; Qiu YH; Kornblau SM; Kimura S; Andreeff M; Kojima K
Cancer Sci; 2015 Dec; 106(12):1705-13. PubMed ID: 26450753
[TBL] [Abstract][Full Text] [Related]
29. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ
Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589
[TBL] [Abstract][Full Text] [Related]
30. [A TIM-3/galectin-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemia progression].
Kikushige Y
Rinsho Ketsueki; 2016 Apr; 57(4):412-6. PubMed ID: 27169443
[TBL] [Abstract][Full Text] [Related]
31. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34
Murone M; Radpour R; Attinger A; Chessex AV; Huguenin AL; Schürch CM; Banz Y; Sengupta S; Aguet M; Rigotti S; Bachhav Y; Massière F; Ramachandra M; McAllister A; Riether C
Mol Cancer Ther; 2017 Aug; 16(8):1497-1510. PubMed ID: 28468777
[TBL] [Abstract][Full Text] [Related]
32. CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML).
Jiang Y; Xu P; Yao D; Chen X; Dai H
Med Sci Monit; 2017 Apr; 23():1725-1732. PubMed ID: 28391288
[TBL] [Abstract][Full Text] [Related]
33. Expression of poliovirus receptor-related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategies.
Graf M; Reif S; Hecht K; Kroell T; Nuessler V; Schmetzer H
Eur J Haematol; 2005 Dec; 75(6):477-84. PubMed ID: 16313259
[TBL] [Abstract][Full Text] [Related]
34. TIM-3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways.
Kikushige Y
Cancer Sci; 2021 Sep; 112(9):3419-3426. PubMed ID: 34159709
[TBL] [Abstract][Full Text] [Related]
35. Phenotyping and Target Expression Profiling of CD34
Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
[TBL] [Abstract][Full Text] [Related]
36. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
[TBL] [Abstract][Full Text] [Related]
37. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.
Kikushige Y; Miyamoto T
Int J Hematol; 2013 Dec; 98(6):627-33. PubMed ID: 24046178
[TBL] [Abstract][Full Text] [Related]
38. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
Kikushige Y; Akashi K
Ann N Y Acad Sci; 2012 Aug; 1266():118-23. PubMed ID: 22901263
[TBL] [Abstract][Full Text] [Related]
39. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
40. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway.
Zhang Y; Chen HX; Zhou SY; Wang SX; Zheng K; Xu DD; Liu YT; Wang XY; Wang X; Yan HZ; Zhang L; Liu QY; Chen WQ; Wang YF
Mol Cancer; 2015 Mar; 14():56. PubMed ID: 25890196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
